封面
市場調查報告書
商品編碼
2169830

寵物皮膚病市場預測至2034年-按疾病、治療、寵物品種、通路和地區分類的全球分析

Pet Dermatology Market Forecasts to 2034 - Global Analysis By Condition, Treatment Type, Pet Type, Distribution Channel, and By Geography

出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據,預計到 2026 年,全球寵物皮膚病市場規模將達到 26 億美元,並在預測期內以 8.8% 的複合年成長率成長,到 2034 年將達到 51 億美元。

寵物皮膚科涵蓋伴侶動物皮膚、毛髮、耳部及相關發炎性疾病的診斷、預防和治療。該市場包括異位性皮膚炎、過敏性皮膚炎、寄生蟲性皮膚病、細菌和真菌感染疾病以及其他發炎性和自體免疫皮膚病。治療方案包括藥物、藥用洗髮精和外用藥物、診斷測試、治療性食品和營養補充劑。犬、貓和其他伴侶動物可透過獸醫院、動物診所、獸藥店和線上管道獲得皮膚病學護理。人們對動物健康的日益關注、對專業獸醫護理需求的成長以及皮膚病學治療和診斷技術的進步正在推動市場發展。

過敏性皮膚病的盛行率不斷上升,對獸醫護理的需求也日益成長。

伴侶動物過敏性和發炎性皮膚病的診斷和治療需求日益成長,是寵物皮膚病市場的主要驅動力。犬貓可能出現持續搔癢、皮膚發炎、感染疾病和毛髮異常等症狀,這些都需要獸醫的評估和持續治療。環境過敏原、跳蚤感染、食物過敏和繼發性感染都可能導致皮膚病復發。飼主對寵物健康和生活品質的日益關注,促使他們更早地帶寵物就診,並增加處方藥的使用。標靶治療的進步,包括單株抗體和其他特效藥物,也拓展了治療選擇,並進一步推動了對寵物皮膚病專科服務的需求。

治療費用高且慢性皮膚病管理面臨許多挑戰

獸醫諮詢、診斷測試、處方藥和反覆後續觀察的費用可能會限制寵物獲得專業皮膚病服務的機會。慢性疾病,例如異位性皮膚炎,可能需要長期管理,包括調整藥物、局部護理、避免接觸過敏原和定期後續觀察。這些持續的費用會對家庭經濟造成負擔,尤其是在寵物保險覆蓋範圍有限的情況下。此外,由於過敏性疾病、寄生蟲疾病、細菌性疾病和真菌性疾病的皮膚症狀都很通用,因此在選擇治療方案之前進行準確診斷至關重要。另外,需要頻繁用藥或持續改變生活方式的治療方案可能難以堅持,這可能會影響臨床療效和治療的連續性。

標靶治療和獸醫皮膚病診斷技術的進展

獸醫治療和診斷技術的創新為市場拓展創造了巨大的機會。標靶治療旨在抑制過敏性發炎和搔癢,為患有慢性皮膚病的犬隻提供了新的治療選擇。細胞學、微生物學、過敏評估和其他獸醫實驗室服務的診斷檢測技術的進步,有助於更準確地識別潛在病因並選擇合適的治療方案。外用藥物、藥用洗髮精、皮膚屏障產品和治療性營養食品的研發也為疾病管理提供了補充手段。此外,獸醫遠距醫療、數位化病歷和臨床教育的進步,使獸醫能夠後續觀察疾病復發,並改善犬隻獲得專業皮膚病護理的途徑。

抗菌素抗藥性和治療藥物競爭

寵物皮膚病市場面臨抗生素抗藥性、治療限制以及現有療法與新興療法之間競爭等挑戰。抗生素和抗真菌藥物的反覆和不當使用使皮膚感染疾病的治療更加複雜,凸顯了合理用藥的重要性。治療方案的選擇也會受到疾病嚴重程度、動物年齡、潛在疾病以及個別反應差異的影響。老牌製藥公司與提供替代製劑、學名藥、外用溶液和治療性食品的製造商競爭。此外,動物用藥品的監管要求和產品核可程序會增加研發成本並延長上市時間。維持治療的安全性、有效性和臨床可靠性對於市場的永續發展至關重要。

新型冠狀病毒(COVID-19)的影響:

新冠疫情透過改變診所就診途徑、預約安排、供應鏈以及寵物飼主的購買行為,對獸醫皮膚病學產生了影響。常規獸醫服務的臨時限制和中斷導致部分諮詢和後續觀察治療延誤,而急診病例仍需特殊處理。疫情期間寵物領養數量的增加以及人們對伴侶動物福利意識的提高,支撐了多個市場對獸醫服務的需求。遠距醫療和數位化溝通在初步評估和協調後續治療方面也變得越來越重要。疫情後,獸醫醫院繼續滿足對常規和專科服務的需求,包括過敏性皮膚病、感染疾病和寄生蟲疾病的診斷和長期治療。

在預測期內,「異位性皮膚炎和過敏性皮膚炎」細分市場預計將佔據最大佔有率。

異位性皮膚炎和過敏性皮膚炎預計將佔據寵物皮膚病市場最大的佔有率,這主要得益於過敏性皮膚病的複發性和持續獸醫管理的必要性。犬特異性皮膚炎、跳蚤過敏性皮膚炎和其他超敏反應相關疾病可導致持續性搔癢、發炎、皮膚損傷和繼發性感染。治療方法包括處方藥、外用藥、過敏原管理、治療性飲食和定期獸醫後續觀察。隨著標靶治療(包括作用於特定發炎路徑的療法)的出現,患病動物的臨床治療選擇正在增加。寵物飼主日益增強的意識和對改善症狀管理的不斷成長的需求,都鞏固了該領域的領先地位。

預計在預測期內,「診斷測試」領域將實現強勁成長。

隨著獸醫師越來越重視準確識別皮膚病病因,診斷檢測領域預計將迎來強勁成長。由於皮膚病可能由過敏、寄生蟲、細菌感染疾病、真菌感染疾病或這些因素的組合引起,因此適當的診斷評估對於有效治療至關重要。皮膚細胞學檢查、皮膚刮片檢查、真菌檢測、微生物培養和過敏相關評估指南臨床決策,並有助於減少對試驗療法的依賴。獸醫檢測服務的普及和診斷技術的進步正在推動該領域的成長。此外,合理使用抗生素和個人化治療的重要性日益凸顯,也進一步增強了對診斷解決方案的需求。

市佔率最大的地區:

在預測期內,北美預計將佔據全球寵物皮膚病市場最大的佔有率,這得益於其完善的獸醫基礎設施、高額的寵物保健支出以及獸藥和診斷服務的廣泛普及。美國是重要的區域市場,擁有成熟的動物用藥品公司、獸醫院、專科診所和處方藥分銷網路。人們對慢性皮膚病的認知不斷提高,以及針對性皮膚病治療方案的出現,都推動了對獸醫服務的持續需求。此外,完善的診斷實驗室和對動物健康研究的投資也進一步鞏固了該地區的市場地位。

複合年成長率最高的地區:

預計亞太地區在預測期內將實現最高的複合年成長率,主要促進因素包括寵物飼養量的增加、獸醫服務基礎設施的完善以及人們對寵物健康和衛生意識的提高。中國、日本、印度、韓國和澳洲在皮膚病藥物、診斷服務和專業獸醫護理方面蘊藏著巨大的市場機會。都市化和家庭生活方式的改變促使人們更加關注寵物福利,而獸醫院的增加和線上銷售管道的拓展則提高了寵物保健產品的可及性。預計對動物健康領域投資的增加以及先進療法的普及將進一步推動該地區的市場成長。

免費客製化服務:

所有購買此報告的客戶均可享受以下免費自訂選項之一:

  • 企業概況
    • 對其他市場參與者(最多 3 家公司)進行全面分析
    • 對主要公司進行SWOT分析(最多3家公司)
  • 區域細分
    • 根據客戶的興趣,我們將提供主要國家的市場估算和預測,以及複合年成長率(需進行可行性評估)。
  • 競爭性標竿分析
    • 根據產品系列、企業發展和策略聯盟對重點公司進行基準分析。

目錄

第1章:執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章:研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章:競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章:全球寵物皮膚病市場:依疾病分類

  • 異位性皮膚炎和過敏性皮膚炎
  • 寄生蟲性皮膚病
  • 細菌和真菌感染疾病
  • 其他發炎性和自體免疫皮膚病

第6章:全球寵物皮膚病市場:依治療類型分類

  • 製藥
  • 藥用洗髮精和外用製劑
  • 診斷測試
  • 治療性食品和補充劑

第7章:全球寵物皮膚病市場:依寵物類型分類

  • 狗
  • 貓
  • 其他伴侶動物

第8章:全球寵物皮膚病市場:依通路分類

  • 獸醫醫院和獸醫診所
  • 動物用藥品
  • 線上管道

第9章:全球寵物皮膚病市場:依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區(RoW)
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第10章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第11章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第12章:公司簡介

  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim
  • Virbac
  • Dechra Pharmaceuticals PLC
  • Ceva Sante Animale
  • Vetoquinol SA
  • IDEXX Laboratories, Inc.
  • Heska Corporation
  • Nextmune
Product Code: SMRC40473

According to Stratistics MRC, the Global Pet Dermatology Market is accounted for $2.6 billion in 2026 and is expected to reach $5.1 billion by 2034 growing at a CAGR of 8.8% during the forecast period. Pet dermatology encompasses the diagnosis, prevention, and treatment of skin, coat, ear, and related inflammatory conditions in companion animals. The market includes atopic and allergic dermatitis, parasitic skin conditions, bacterial and fungal infections, and other inflammatory and autoimmune skin conditions. Treatment options include pharmaceuticals, medicated shampoos and topicals, diagnostic tests, and therapeutic diets and supplements. Dogs, cats, and other companion animals receive dermatological care through veterinary clinics and hospitals, veterinary pharmacies, and online channels. Rising awareness of animal health, increasing demand for specialized veterinary care, and advances in dermatological therapeutics and diagnostics are supporting market development.

Market Dynamics:

Driver:

Increasing prevalence of allergic skin conditions and rising demand for veterinary care

The growing need to diagnose and manage allergic and inflammatory skin conditions in companion animals is a major driver of the pet dermatology market. Dogs and cats can experience persistent itching, skin inflammation, infections, and coat disorders that require veterinary assessment and ongoing treatment. Environmental allergens, flea infestations, food sensitivities, and secondary infections can contribute to recurring dermatological problems. Increasing awareness among pet owners regarding animal comfort and quality of life is encouraging earlier veterinary consultations and greater use of prescription treatments. Advances in targeted therapies, including monoclonal antibodies and other specialized medications, are also expanding treatment options and supporting demand for professional pet dermatology services.

Restraint:

High treatment costs and challenges in managing chronic dermatological conditions

The cost of veterinary consultations, diagnostic testing, prescription medications, and repeated follow-up visits can restrict access to specialized pet dermatology services. Chronic conditions such as atopic dermatitis may require long-term management, including medication adjustments, topical care, allergen avoidance, and regular monitoring. These recurring expenses can place pressure on household budgets, particularly where pet insurance coverage is limited. In addition, dermatological symptoms can overlap across allergic, parasitic, bacterial, and fungal conditions, making accurate diagnosis important before treatment selection. Treatment adherence may also be challenging when therapies require frequent administration or sustained lifestyle changes, potentially affecting clinical outcomes and continuity of care.

Opportunity:

Advancements in targeted therapeutics and veterinary dermatology diagnostics

Innovation in veterinary therapeutics and diagnostic technologies presents significant opportunities for market expansion. Targeted treatments designed to control allergic inflammation and itching are creating additional options for dogs with chronic dermatological conditions. Advances in diagnostic testing, including cytology, microbial testing, allergy assessment, and other veterinary laboratory services, can support more accurate identification of underlying causes and appropriate treatment selection. The development of topical formulations, medicated shampoos, skin barrier products, and therapeutic nutrition also provides complementary approaches to disease management. Furthermore, veterinary teleconsultation, digital patient records, and improved clinical education can help practitioners monitor recurring conditions and strengthen access to specialized dermatological care.

Threat:

Antimicrobial resistance and competition among treatment alternatives

The pet dermatology market faces challenges associated with antimicrobial resistance, treatment limitations, and competition among established and emerging therapies. Repeated or inappropriate use of antibiotics and antifungal medications can complicate the management of skin infections and increase the importance of responsible prescribing practices. Treatment selection may also be affected by differences in disease severity, animal age, underlying health conditions, and individual response. Established pharmaceutical companies compete with manufacturers offering alternative formulations, generic medicines, topical products, and therapeutic diets. In addition, regulatory requirements for veterinary medicines and product approvals can increase development costs and extend commercialization timelines. Maintaining treatment safety, efficacy, and clinical confidence remains important for sustained market growth.

Covid-19 Impact:

The COVID-19 pandemic affected veterinary dermatology through changes in clinic access, appointment availability, supply chains, and pet owners' purchasing behavior. Temporary restrictions and disruptions to routine veterinary services delayed some consultations and follow-up visits, while urgent cases continued to require professional attention. The growth of pet adoption and increased attention to companion animal well-being during the pandemic supported demand for veterinary services in several markets. Teleconsultation and digital communication also gained importance for preliminary assessments and ongoing care coordination. Following the pandemic, veterinary practices have continued to address demand for routine and specialized services, including the diagnosis and long-term management of allergic skin disorders, infections, and parasitic conditions.

The Atopic and Allergic Dermatitis segment is expected to be the largest during the forecast period

The Atopic and Allergic Dermatitis segment is expected to account for the largest share of the pet dermatology market, driven by the recurring nature of allergic skin disorders and the need for sustained veterinary management. Canine atopic dermatitis, flea allergy dermatitis, and other hypersensitivity-related conditions can cause persistent itching, inflammation, skin lesions, and secondary infections. Management may involve prescription pharmaceuticals, topical treatments, allergen control, therapeutic diets, and regular veterinary monitoring. The availability of targeted therapies, including treatments that address specific inflammatory pathways, is expanding clinical options for affected animals. Growing pet owner awareness and demand for improved symptom control are supporting the segment's leading position.

The Diagnostic Tests segment is expected to witness strong growth during the forecast period

The Diagnostic Tests segment is expected to experience strong growth as veterinary practitioners increasingly emphasize accurate identification of the causes of dermatological symptoms. Skin conditions may arise from allergies, parasites, bacterial infections, fungal infections, or combinations of these factors, making appropriate diagnostic evaluation important for effective treatment. Skin cytology, skin scrapings, fungal testing, microbial culture, and allergy-related assessments can help guide clinical decisions and reduce reliance on trial-and-error treatment. Growing access to veterinary laboratory services and advances in diagnostic technologies are supporting adoption. The increasing importance of antimicrobial stewardship and personalized treatment selection is also strengthening demand for diagnostic solutions.

Region with largest share:

During the forecast period, North America is expected to hold the largest share of the Global Pet Dermatology Market, supported by established veterinary healthcare infrastructure, high expenditure on companion animal care, and broad availability of veterinary pharmaceuticals and diagnostic services. The United States represents a major regional market, with established animal health companies, veterinary hospitals, specialist practices, and distribution networks for prescription treatments. Growing awareness of chronic skin conditions and the availability of targeted dermatological therapies support demand for ongoing veterinary care. Established diagnostic laboratories and investment in animal health research further strengthen the region's market position.

Region with highest CAGR:

Asia Pacific is expected to register the highest CAGR during the forecast period, driven by growing companion animal ownership, expanding veterinary service infrastructure, and increasing awareness of pet health and hygiene. China, Japan, India, South Korea, and Australia provide important opportunities for dermatological medicines, diagnostic services, and specialized veterinary care. Urbanization and changing household lifestyles are encouraging greater attention to companion animal well-being, while expanding veterinary clinics and online distribution channels are improving access to pet healthcare products. Increasing investment in animal health and the availability of advanced treatment options are expected to support regional market growth.

Key players in the market

Some of the key players in the Global Pet Dermatology Market include Zoetis Inc., Elanco Animal Health Incorporated, Boehringer Ingelheim, Virbac, Dechra Pharmaceuticals PLC, Ceva Sante Animale, Vetoquinol S.A., IDEXX Laboratories, Inc., Heska Corporation, and Nextmune.

Key Developments:

In October 2026, Zoetis Inc. announced FDA approval of Convenia RTU for Dogs, a concentrated cefovecin injectable formulation for treating susceptible bacterial skin infections in dogs. The formulation is designed to deliver the required dose in a smaller injection volume, expanding treatment options for canine dermatological infections.

In September 2026, Elanco Animal Health Incorporated highlighted the growing importance of year-round parasite and allergy management, noting that changing seasonal patterns are extending demand for tick prevention and dermatology treatments. The company emphasized innovation across its pet health portfolio to address evolving veterinary and pet owner needs.

In August 2026, Virbac organized a scientific veterinary dermatology tour in China, bringing together veterinarians in Beijing and Shanghai for clinical discussions on canine atopic dermatitis, otology, diagnosis, and treatment management. The initiative supported veterinary education and the exchange of dermatological expertise.

In May 2026, Elanco Animal Health Incorporated initiated the phased launch of Befrena (tirnovetmab), an anti-IL-31 monoclonal antibody injection for canine allergic and atopic dermatitis in the United States. The treatment was introduced as an additional option for controlling allergic itch, with a dosing interval of six to eight weeks.

Conditions Covered:

  • Atopic and Allergic Dermatitis
  • Parasitic Skin Conditions
  • Bacterial and Fungal Infections
  • Other Inflammatory and Autoimmune Skin Conditions

Treatment Types Covered:

  • Pharmaceuticals
  • Medicated Shampoos and Topicals
  • Diagnostic Tests
  • Therapeutic Diets and Supplements

Pet Types Covered:

  • Dogs
  • Cats
  • Other Companion Animals

Distribution Channels Covered:

  • Veterinary Clinics and Hospitals
  • Veterinary Pharmacies
  • Online Channels

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for regional and country-level segments
  • Strategic recommendations for new entrants
  • Covers market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032, and 2034
  • Market trends, including drivers, constraints, opportunities, threats, challenges, investment opportunities, and recommendations
  • Strategic recommendations for key business segments based on market estimations
  • Competitive landscape mapping and assessment of key industry trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends and assessment of the latest technological advancements

Free Customization Offerings:

All customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, forecasts, and CAGR of any prominent country as per the client's interest (subject to feasibility assessment)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Pet Dermatology Market, By Condition

  • 5.1 Atopic and Allergic Dermatitis
  • 5.2 Parasitic Skin Conditions
  • 5.3 Bacterial and Fungal Infections
  • 5.4 Other Inflammatory and Autoimmune Skin Conditions

6 Global Pet Dermatology Market, By Treatment Type

  • 6.1 Pharmaceuticals
  • 6.2 Medicated Shampoos and Topicals
  • 6.3 Diagnostic Tests
  • 6.4 Therapeutic Diets and Supplements

7 Global Pet Dermatology Market, By Pet Type

  • 7.1 Dogs
  • 7.2 Cats
  • 7.3 Other Companion Animals

8 Global Pet Dermatology Market, By Distribution Channel

  • 8.1 Veterinary Clinics and Hospitals
  • 8.2 Veterinary Pharmacies
  • 8.3 Online Channels

9 Global Pet Dermatology Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 Zoetis Inc.
  • 12.2 Elanco Animal Health Incorporated
  • 12.3 Boehringer Ingelheim
  • 12.4 Virbac
  • 12.5 Dechra Pharmaceuticals PLC
  • 12.6 Ceva Sante Animale
  • 12.7 Vetoquinol S.A.
  • 12.8 IDEXX Laboratories, Inc.
  • 12.9 Heska Corporation
  • 12.10 Nextmune

List of Tables

  • Table 1 Global Pet Dermatology Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Pet Dermatology Market Outlook, By Condition (2023-2034) ($MN)
  • Table 3 Global Pet Dermatology Market Outlook, By Atopic and Allergic Dermatitis (2023-2034) ($MN)
  • Table 4 Global Pet Dermatology Market Outlook, By Parasitic Skin Conditions (2023-2034) ($MN)
  • Table 5 Global Pet Dermatology Market Outlook, By Bacterial and Fungal Infections (2023-2034) ($MN)
  • Table 6 Global Pet Dermatology Market Outlook, By Other Inflammatory and Autoimmune Skin Conditions (2023-2034) ($MN)
  • Table 7 Global Pet Dermatology Market Outlook, By Treatment Type (2023-2034) ($MN)
  • Table 8 Global Pet Dermatology Market Outlook, By Pharmaceuticals (2023-2034) ($MN)
  • Table 9 Global Pet Dermatology Market Outlook, By Medicated Shampoos and Topicals (2023-2034) ($MN)
  • Table 10 Global Pet Dermatology Market Outlook, By Diagnostic Tests (2023-2034) ($MN)
  • Table 11 Global Pet Dermatology Market Outlook, By Therapeutic Diets and Supplements (2023-2034) ($MN)
  • Table 12 Global Pet Dermatology Market Outlook, By Pet Type (2023-2034) ($MN)
  • Table 13 Global Pet Dermatology Market Outlook, By Dogs (2023-2034) ($MN)
  • Table 14 Global Pet Dermatology Market Outlook, By Cats (2023-2034) ($MN)
  • Table 15 Global Pet Dermatology Market Outlook, By Other Companion Animals (2023-2034) ($MN)
  • Table 16 Global Pet Dermatology Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 17 Global Pet Dermatology Market Outlook, By Veterinary Clinics and Hospitals (2023-2034) ($MN)
  • Table 18 Global Pet Dermatology Market Outlook, By Veterinary Pharmacies (2023-2034) ($MN)
  • Table 19 Global Pet Dermatology Market Outlook, By Online Channels (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.